Esperion Therapeutics, Inc.

Analysis for Ticker: ESPR

Esperion Therapeutics Inc is a pharmaceutical business that develops oral pills like NEXLETOL and NEXLIZET to help people lower their cholesterol by blocking an enzyme called ACLY. The company is effectively being liquidated through an acquisition by an investment firm called ARCHIMED for approximately 800,53$ million. The math is a disaster because the people in charge have spent months printing millions of new shares to pay themselves while the business burns cash. On 16/04/2026, the company revealed that the chief executive officer Sheldon L Koenig was paid 7,09$ million for one year of work, even as the stock price sat at a low 2,74$ in 03/2026. The management is asking for 7,0 million more shares to be added to their pay pool, which already holds 30,15 million shares ready to be handed out for free. The bleeding is absolute; the company has already mortgaged its future revenue from Japan and Europe to lenders, leaving almost nothing for the people who actually own the stock.